Leading expert in multiple myeloma, Dr. Nikhil Munshi, MD, explains the latest advances in blood cancer treatment. He is a professor at Harvard Medical School and Director at Dana Farber Cancer Institute. Dr. Munshi's pioneering research has directly led to the development of precision medicine therapies for myeloma, including CAR-T cell therapy and immunotherapy.
Mehr von DiagnosticDetectives.Com
Advances in Multiple Myeloma Treatment and Research
Jump To Section
- Expert Background and Credentials
- Multiple Myeloma Overview
- Research Breakthroughs in Myeloma Genetics
- Precision Medicine Therapies
- Professional Leadership and Recognition
- Full Transcript
Expert Background and Credentials
Dr. Nikhil Munshi, MD, is a world-renowned multiple myeloma expert. He holds a prestigious position as Professor of Medicine at Harvard Medical School. Dr. Munshi serves as the Director of Basic and Correlative Science and Associate Director of the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute.
He is also an attending physician at Brigham and Women’s Hospital and the Boston VA Healthcare System. Dr. Munshi received his medical degree from Maharaja Sayjirao University in India. He completed fellowships in medical oncology at Johns Hopkins and hematology/oncology at Indiana University.
Multiple Myeloma Overview
Multiple myeloma is the second most common blood cancer. It is a malignancy of plasma cells in the bone marrow. This cancer can lead to bone damage, kidney problems, and impaired immune function. Early diagnosis and advanced treatment are crucial for improving patient outcomes.
Dr. Nikhil Munshi, MD, has dedicated his career to understanding this complex disease. His work has transformed how clinicians approach multiple myeloma treatment. Dr. Anton Titov, MD, discusses these advancements with the leading expert.
Research Breakthroughs in Myeloma Genetics
Dr. Nikhil Munshi, MD, has conducted pioneering research in multiple myeloma genetics. His groundbreaking work has identified key genetic drivers of the disease. These discoveries have provided critical insights into myeloma pathogenesis and progression.
Understanding the genetic basis of myeloma allows for more targeted treatment approaches. Dr. Munshi's research has been published in over 500 peer-reviewed articles. His contributions have fundamentally advanced the field of hematologic oncology.
Precision Medicine Therapies
The research conducted by Dr. Nikhil Munshi, MD, directly led to development of precision medicine therapies. These include innovative immunotherapies and CAR-T cell treatments for multiple myeloma. Targeted therapies using small molecules and biologics have emerged from his work.
These cutting-edge treatments represent a shift toward personalized cancer care. They offer new hope for patients with relapsed or refractory disease. Dr. Munshi's contributions have significantly improved treatment options for myeloma patients worldwide.
Professional Leadership and Recognition
Dr. Nikhil Munshi, MD, is a founding member and current president of the International Myeloma Society. He has served on numerous national committees, including the National Cancer Institute's Clinical Trials and Translational Research Advisory Committee. His leadership has shaped myeloma research priorities globally.
Dr. Munshi has received the prestigious Waldenström's Award for Distinguished Lifetime Achievement in Myeloma Research. He is also a recipient of the Dr. B.C. Roy National Award and the Robert Kyle Award. These honors recognize his extraordinary contributions to hematology and oncology.
Full Transcript
Hello! We are with Dr. Nikhil Munshi, a world-renowned multiple myeloma blood cancer expert. Dr. Munshi joins from Boston. We will discuss multiple myeloma, the second most common blood cancer.
Dr. Munshi is a Professor of Medicine at the Harvard Medical School and the Director of Basic and Correlative Science, and Associate Director of the Jerome Lipper Multiple Myeloma Center and Kraft Professor of Medicine at the Dana Farber Cancer Institute. Dr. Munshi is an attending physician at the Brigham and Women’s Hospital and the Boston VA Healthcare System, Harvard Medical School.
Dr. Munshi received his MD from the Maharaja Sayjirao University in India. He completed a Research Fellowship in Medical Oncology at the Johns Hopkins Oncology Center and a clinical fellowship in hematology/oncology at Indiana University Medical Center.
Professor Munshi has done pioneering research in the genetics of multiple myeloma. His breakthrough work directly led to the development of cutting-edge precision medicine therapies for multiple myeloma, such as immunotherapy, CAR-T therapy, as well as multiple small molecule- and biologics-based targeted therapy for multiple myeloma.
Professor Munshi is a founding member and current president of the International Myeloma Society. Professor Munshi has served as a co-chair of the National Steering Committee on Myeloma at the National Cancer Institute and as a member of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.
Dr. Munshi was awarded the most prestigious award in myeloma, the “Waldenström’s Award”, for the most Distinguished Lifetime Achievement in Myeloma Research, the Dr. B.C. Roy National Award by the president of India, Robert Kyle Award in 2021 and a lifetime achievement award from Association of VA Hematologists and Oncologists.
Professor Munshi published over 500 articles in peer-reviewed medical journals and authored multiple books and book chapters on multiple myeloma and other blood cancers.
Dr. Anton Titov, MD: Professor Munshi, hello and welcome!
Dr. Nikhil Munshi, MD: Hello, it's my pleasure to be here. Thank you for your kind introduction.